{"address1": "25 North 38th Street", "address2": "11th Floor", "city": "Philadelphia", "state": "PA", "zip": "19104", "country": "United States", "phone": "267 817 5790", "website": "https://www.centurytx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.", "fullTimeEmployees": 140, "companyOfficers": [{"maxAge": 1, "name": "Mr. Brent  Pfeiffenberger M.B.A., Pharm.D.", "title": "CEO & Director", "fiscalYear": 2023, "totalPay": 274065, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Adrienne  Farid Ph.D.", "age": 62, "title": "Chief Development Officer, CCO & Head of Early Development", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 670289, "exercisedValue": 0, "unexercisedValue": 509880}, {"maxAge": 1, "name": "Dr. Gregory  Russotti Ph.D.", "age": 57, "title": "Chief Technology & Manufacturing Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 852564, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Morgan  Conn Ph.D.", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chad A. Cowan Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shane  Williams Ph.D.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Michael  Naso Ph.D.", "title": "Senior VP of Cell Engineering", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nick  Trede M.D., Ph.D.", "title": "Senior VP & Head of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Katja  Buhrer", "age": 42, "title": "SVP, Head of Corporate Affairs & Strategy", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas  Carr CPA", "title": "Senior VP of Finance & Operations and Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.476, "open": 0.4852, "dayLow": 0.4512, "dayHigh": 0.4927, "regularMarketPreviousClose": 0.476, "regularMarketOpen": 0.4852, "regularMarketDayLow": 0.4512, "regularMarketDayHigh": 0.4927, "payoutRatio": 0.0, "beta": 1.755, "forwardPE": -0.33466664, "volume": 597877, "regularMarketVolume": 597877, "averageVolume": 497601, "averageVolume10days": 602020, "averageDailyVolume10Day": 602020, "bid": 0.3397, "ask": 0.5877, "bidSize": 1, "askSize": 1, "marketCap": 38875132, "fiftyTwoWeekLow": 0.451, "fiftyTwoWeekHigh": 4.428, "priceToSalesTrailing12Months": 5.900005, "fiftyDayAverage": 0.691, "twoHundredDayAverage": 1.444255, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -96586856, "profitMargins": 0.0, "floatShares": 39812176, "sharesOutstanding": 86045000, "sharesShort": 3375202, "sharesShortPriorMonth": 3125318, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0392, "heldPercentInsiders": 0.27484, "heldPercentInstitutions": 0.57263, "shortRatio": 7.24, "shortPercentOfFloat": 0.0479, "impliedSharesOutstanding": 86045000, "bookValue": 1.88, "priceToBook": 0.24031915, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -126566000, "trailingEps": -1.61, "forwardEps": -1.35, "enterpriseToRevenue": -14.659, "enterpriseToEbitda": 0.793, "52WeekChange": -0.87783784, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.4518, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 5.4, "targetMedianPrice": 5.0, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 189292000, "totalCashPerShare": 2.2, "ebitda": -121862000, "totalDebt": 53830000, "quickRatio": 1.47, "currentRatio": 1.495, "totalRevenue": 6589000, "debtToEquity": 33.36, "revenuePerShare": 0.084, "returnOnAssets": -0.23667, "returnOnEquity": -0.73136, "grossProfits": -100655000, "freeCashflow": 49435248, "operatingCashflow": -110135000, "revenueGrowth": 14.571, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -8.22262, "financialCurrency": "USD", "symbol": "IPSC", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketTime": 1743537602, "marketState": "PRE", "regularMarketChangePercent": -5.0840383, "regularMarketPrice": 0.4518, "shortName": "Century Therapeutics, Inc.", "longName": "Century Therapeutics, Inc.", "exchange": "NMS", "messageBoardId": "finmb_626518430", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketChange": -0.024200022, "regularMarketDayRange": "0.4512 - 0.4927", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 497601, "fiftyTwoWeekLowChange": 0.00079998374, "fiftyTwoWeekLowChangePercent": 0.0017737999, "fiftyTwoWeekRange": "0.451 - 4.428", "fiftyTwoWeekHighChange": -3.9762, "fiftyTwoWeekHighChangePercent": -0.8979675, "fiftyTwoWeekChangePercent": -87.78378, "epsTrailingTwelveMonths": -1.61, "epsForward": -1.35, "epsCurrentYear": -0.27, "priceEpsCurrentYear": -1.6733332, "fiftyDayAverageChange": -0.2392, "fiftyDayAverageChangePercent": -0.34616497, "twoHundredDayAverageChange": -0.992455, "twoHundredDayAverageChangePercent": -0.6871744, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-18", "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "displayName": "Century Therapeutics", "trailingPegRatio": null}